Loading clinical trials...
Loading clinical trials...
A 3-Year, Multi-Center, Long-Term Safety (LTS) Study to Evaluate the Safety and Tolerability of TD-1473 in Subjects With Ulcerative Colitis (UC)
Conditions
Interventions
TD-1473 Dose A
TD-1473 Dose B
+1 more
Locations
184
United States
Theravance Biopharma Investigational Site
Chula Vista, California, United States
Theravance Biopharma Investigational Site
Lancaster, California, United States
Theravance Biopharma Investigational Site
Orange, California, United States
Theravance Biopharma Investigational Site
Colorado Springs, Colorado, United States
Theravance Biopharma Investigational Site
Aventura, Florida, United States
Theravance Biopharma Investigational Site
Clearwater, Florida, United States
Start Date
July 23, 2020
Primary Completion Date
October 27, 2021
Completion Date
October 27, 2021
Last Updated
November 2, 2022
NCT07374471
NCT07271069
NCT07245394
NCT07333716
NCT06896305
NCT07350577
Lead Sponsor
Theravance Biopharma
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions